In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Congress has been debating and discussing pharmacy benefit manager (PBM) legislation for more than a year. At least three Senate committees have considered PBM bills, and the leaders of the Senate Finance Committee released a letter last month vowing to enact “meaningful pharmacy benefit manager (PBM) reforms this Congress." The House passed a sweeping healthcare bill in December 2023 by a wide bipartisan margin that included provisions affecting PBMs.
Patrick Cooney doesn’t think the senators and representatives are going to let all that work and momentum on PBM legislation go to waste.
“I do believe that at the end of the day, whether it’s the summer or during a lame-duck session we are going to see something on the president’s desk,” said Cooney, president of The Federal Group, during this episode of Managed Healthcare Executive’s "DC Roundtable” podcast.
The Federal Group is a lobbying and advocacy firm that has a number of healthcare igroups as clients, including the American College of Nurse-Midwives, the Medical Device Manufacturers Association and the Emergency Care Research Institute. Cooney is also a consultant to the Pharmacy Benefit Management Institute (PBMI), which is owned by MJH Life Sciences, the parent company that owns Managed Healthcare Executive.
During the "DC Roundtable" podcast, Cooney also said he expects any agreed-upon legislation to be fairly broad, not just limited to Medicare and Medicaid beneficiaries, and that ERISA plans are likely to affected. (ERISA stands for the Employee Retirement Income Security Act, and ERISA plans are health insurance plans established by employers who self insure). He also expects to see the provisions that address spread pricing by PBMs and increased reporting requirements.
“PBMs can expect more requirements to report information and some restrictions on actual practices,” Cooney said.
But Cooney also said that that “there is some level of understanding that we can’t completely micromanage this industry. I mean there are huge benefits to be had by having PBMs do the work they do."
The 2024 Asembia Meeting is Underway
April 29th 2024GLP-1s, artificial intelligence and the Inflation Reduction Act are among the topics featured in the education sessions of the specialty pharmacy meeting in Las Vegas. The keynote speaker is William McRaven, a retired four-star admiral and former chancellor of the University of Texas system.
Read More
FDA Update for Week of April 22, 2024: Second Gene Therapy for Hemophilia B
April 27th 2024This week, the FDA has approved several products, including Beqvez, the second gene therapy hemophilia B; Ojemda for children with brain tumors; an additional indication for Lutathera for adolescents with neuroendocrine tumors; and a bladder cancer immunotherapy. The agency has also issued a complete response letter for pz-cel to treat epidermolysis bullosa.
Read More